Elixir Clinical Research Co., Ltd. is a technology-based full service CRO based in China. Founded in 2019, Elixir Clinical Research is a benchmark project empowered by Taimei Technology, aimed at supporting innovation and development within the CRO industry. They are committed to accelerating the accessibility of innovative drugs and have provided qualified and effective clinical research solutions to hundreds of pharmaceutical companies, enabling the swift launch of new drugs in the market. The company recently secured a significant $52.00M Series A investment on 26 April 2022 from prominent investors such as Sinovation Ventures, LYFE Capital, and Chow Tai Fook. As a player in the biotechnology and pharmaceutical industries, Elixir Clinical Research is well-positioned to continue its growth trajectory and make a lasting impact in the healthcare and pharmaceutical sectors.
No recent news or press coverage available for Elixir Clinical Research Co., Ltd..